Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc. Common Stock (BCAX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BCAX · as of Sep 30, 2025
Ownership Breakdown
115
Institutional Holders
▲ 9 vs Q2
$789.43M
Total Inst. Value
▲ $314.10M vs Q2
54.78M
Shares Outstanding
freeFloat 64.37%
50.20M
13F Shares Held
▼ 967,138 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BCAX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 6.96M | 12.75% | 12.75% | $109.84B | Nov 14, 2025 | — held |
SIREN, L.L.C. pharmaceutical preparations | 5.22M | 9.57% | 9.57% | $82.38B | Nov 13, 2025 | — held |
VESTAL POINT CAPITAL, LP pharmaceutical preparations | 5.10M | 9.35% | 9.35% | $80.53B | Nov 14, 2025 | ▲ 100.0K |
RED TREE MANAGEMENT, LLC pharmaceutical preparations | 3.17M | 5.81% | 5.81% | $50.06B | Nov 7, 2025 | — held |
TPG GP A, LLC pharmaceutical preparations | 3.01M | 5.52% | 5.52% | $47.53B | Nov 14, 2025 | — held |
FMR LLC pharmaceutical preparations | 2.70M | 4.95% | 4.95% | $42.61B | Nov 13, 2025 | ▲ 160.0K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 2.43M | 4.45% | 4.45% | $38.32B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 2.31M | 4.24% | 4.24% | $36.50B | Nov 12, 2025 | ▲ 200.5K |
OMEGA FUND MANAGEMENT, LLC pharmaceutical preparations | 2.20M | 4.04% | 4.04% | $34.81B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 2.20M | 4.04% | 4.04% | $34.75B | Nov 7, 2025 | ▲ 195.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
23
Increased
+1.93M shares5
New Positions
first time holders8
Decreased
−1.06M shares0
Sold Out
fully exitedNet shares change (top 50)
+866.6K
+1.93M / −1.06M
Net new holders
+20
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BCAX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
10
Buy transactions
18
Sell transactions
0.56
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Hyep Ivan Chief Financial Officer | May 21, 2026 | Sale | 9,200 | $20.42 | $187.9K | 145.4K | Form 4 ↗ |
Mazumdar Claire Chief Executive Officer | May 18, 2026 | Sale | 12,022 | $19.96 | $240.0K | 365.1K | Form 4 ↗ |
Mazumdar Claire Chief Executive Officer | May 18, 2026 | Sale | 2,978 | $20.35 | $60.6K | 362.2K | Form 4 ↗ |
Cohlhepp Ryan President and COO | May 15, 2026 | Sale | 8,000 | $20.29 | $162.3K | 196.1K | Form 4 ↗ |
Cohlhepp Ryan President and COO | May 15, 2026 | Sale | 4,500 | $20.29 | $91.3K | 191.6K | Form 4 ↗ |
Schelman William Chief Medical Officer | May 8, 2026 | Award | 85,000 | $22.58 | $1.92M | 85.0K | Form 4 ↗ |
Raben David Chief Medical Officer | Apr 27, 2026 | Sale | 5,500 | $22.88 | $125.8K | 55.3K | Form 4 ↗ |
Hyep Ivan Chief Financial Officer | Apr 21, 2026 | Sale | 9,200 | $23.00 | $211.6K | 145.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Bicara Therapeutics Inc. Common Stock (BCAX) is primarily owned by institutional investors, who hold approximately 91.6% of total shares outstanding. Company insiders own approximately 35.63%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Bicara Therapeutics Inc. Common Stock is RA CAPITAL MANAGEMENT, L.P., holding approximately 6.96 million shares — equal to 12.75% of outstanding shares — as of September 30, 2025.
A total of 115 institutional investors currently hold BCAX stock, with a combined institutional value of approximately $789,429,889 as of the most recent 13F filing period.
Frequently asked questions
BCAX ownershipBicara Therapeutics Inc. Common Stock (BCAX) is primarily owned by institutional investors, who hold approximately 91.6% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 12.75% stake. Company insiders hold 35.63%. Data sourced from SEC Form 13F as of September 30, 2025.